Abstract 3141
Background
Synovial sarcoma is a high-grade, malignant soft tissue sarcoma (STS) considered as relatively chemosensitive tumor, with particular sensitivity to ifosfamide. The aim of this prospective study was to analyze outcomes of patients (pts) with localized synovial sarcoma treated in a single institution with uniform neo- and adjuvant combined therapy protocol.
Methods
One hundred and seventy one pts (96 women and 75 men) with localized synovial sarcoma were treated at our institution between 1997 and 2014. Chemotherapy consisted of 4 cycles of ifosfamide 12 g/m2 (2 cycles given preoperatively) and two cycles of doxorubicin-based regimen 75 mg/m2. Most pts received neoadjuvant hypofractionated radiation therapy followed by immediate surgery. At a median follow-up of 114 months (range, 3 to 244 months) 69 deaths were recorded.
Results
Median age at diagnosis was 33 years (range 17-69). The most common localization was lower limb (n = 121), followed by upper limb (n = 32). Tumors larger than 5 cm in size were found in 70% of pts (median 8 cm; range 2 – 30 cm). Seventy-seven cases (45%) had primary diagnosed tumor. Sixty-four (37%) pts were referred to our institute after unplanned tumor excision and 30 (18%) pts because of clinical local recurrence. At the time of analysis, 36 (21%) pts had local recurrence (only 8% of pts with primary tumor) and 76 (44%) pts developed metastases. Median disease-free survival was 82 months. The 5-year overall survival (OS), local recurrence-free survival (LRFS) and distant recurrence-free survival (DRFS) rates were 74%, 80% and 60%, respectively. By univariate analysis, unplanned tumor excision (p = 0.0025) and positive margins (p = 0.048) were related to higher risk of local recurrence. In multivariable Cox’s regression, age >35 years (p = 0.045), male sex (p = 0.001), stage IIIB (p < 0.01) and histology other than monophasic (p = 0.033) were associated with worse OS.
Conclusions
In adult patients with localized synovial sarcoma, a long-term survival and local control can be achieved with intensive combined therapy. Our results confirms the importance of planned surgery and clear surgical margins for local control. We have demonstrated that age, sex, disease stage, and histology are independent prognostic factors of overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Funding
Has not received any funding.
Disclosure
H.M. Kosela Paterczyk: Honoraria (institution): Novartis; Honoraria (self): MSD; Honoraria (self): BMS. P. Rutkowski: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Honoraria (self): Roche; Honoraria (self), Speaker Bureau / Expert testimony: Pfizer; Honoraria (self), Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy: Blueprint Medicines. All other authors have declared no conflicts of interest.
Resources from the same session
5239 - Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice
Presenter: Matthew Krebs
Session: Poster Display session 1
Resources:
Abstract
5595 - Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Presenter: Saadettin Kilickap
Session: Poster Display session 1
Resources:
Abstract
5840 - Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance
Presenter: Sebastian Michels
Session: Poster Display session 1
Resources:
Abstract
1905 - NTRK1-3 Genomic Fusions in Non-Small Cell Lung Cancer (NSCLC) Determined by Comprehensive Genomic Profiling
Presenter: Sai-Hong Ou
Session: Poster Display session 1
Resources:
Abstract
3016 - Preferential expression of the affected MET allele in lung carcinomas with heterozygous MET exon 14 skipping mutations: implications for clinical testing
Presenter: Evgeny Imyanitov
Session: Poster Display session 1
Resources:
Abstract
4120 - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew G Krebs
Session: Poster Display session 1
Resources:
Abstract
3764 - Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
4070 - Crizotinib vs Platinum-based Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer with Different ROS1 Fusion Variants
Presenter: Haiyan Xu
Session: Poster Display session 1
Resources:
Abstract
5528 - Genomic and clinical characterization of Non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3
Presenter: Matthias Scheffler
Session: Poster Display session 1
Resources:
Abstract
3779 - The expression of HER2-gene polymorphisms -1985G>T and P1170A C>G and their association with the risk of development of lung adenocarcinoma
Presenter: Ivan Aleric
Session: Poster Display session 1
Resources:
Abstract